The 6th World Symposium on Pulmonary Hypertension: What's Old is New

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2019 Jun 29

PMID 31249672

Citations 66

Authors

David F Condon

Nils P Nickel

Ryan Anderson

Shireen Mirza

Vinicio A de Jesus Perez

Affiliations

Soon will be listed here.

Abstract

In February 2018, the 6th World Symposium on Pulmonary Hypertension (WSPH) brought together experts from various disciplines to review the most relevant clinical and scientific advances in the field of PH over the last 5 years. Based on careful review and discussions by members of the different task forces, major revisions were made on the hemodynamic definition for various forms of PH and new genes were added to the list of genetic markers associated with pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease. In addition, the use of risk stratification tools was encouraged as a strategy to reduce one-year mortality risk in PAH patients through early implementation of PAH therapies. While members of the medical community are still debating some of the proposed changes, the new WSPH guidelines advocate early diagnosis and initiation of combination therapy to reduce mortality and improve quality of life in patients with PH.

Citing Articles

Pediatric Pulmonary Arterial Hypertension; is it Possible to Predict its Outcome?.

Agha H, Hegazy R, Gamal A, Essam R, Elmessih A, Behairy A J Saudi Heart Assoc. 2025; 36(4):408-419.

PMID: 39763633 PMC: 11702901. DOI: 10.37616/2212-5043.1398.

The uses of right heart catheterization in cardio-pulmonary disease: State-of-the-art.

Katbamna B, Wu L, Rodriguez M, King P, Schilling J, Mahar J Am Heart J Plus. 2025; 49:100488.

PMID: 39760109 PMC: 11699050. DOI: 10.1016/j.ahjo.2024.100488.

The hepcidin-ferroportin axis influences mitochondrial function, proliferation, and migration in pulmonary artery endothelial and smooth muscle cells.

Issitt T, Toe Q, Pedersen S, Shackshaft T, Ghazaly M, West L Pulm Circ. 2024; 14(4):e70006.

PMID: 39697901 PMC: 11653027. DOI: 10.1002/pul2.70006.

Hemodynamic and Genetic Associations with the Risk of Idiopathic Pulmonary Arterial Hypertension Development in an Ethnic Cohort of Kazakhs.

Taizhanova D, Nurpissova T, Abildinova G, Martynyuk T, Kulmyrzayeva N, Zholdybayeva E Diagnostics (Basel). 2024; 14(23).

PMID: 39682595 PMC: 11640456. DOI: 10.3390/diagnostics14232687.

Impact of diabetes mellitus on mortality in pulmonary hypertension: A systematic review and meta-analysis.

Padte S, Mehta P, Bansal V, Singh N, Sunasra R, Goyal V World J Crit Care Med. 2024; 13(4):99564.

PMID: 39655305 PMC: 11577532. DOI: 10.5492/wjccm.v13.i4.99564.

References

LUTHY E . Proceedings: The epidemic of primary pulmonary hypertension in Europe. Pathol Microbiol (Basel). 1975; 43(2-O):246-7. View

Kovacs G, Berghold A, Scheidl S, Olschewski H . Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J. 2009; 34(4):888-94. DOI: 10.1183/09031936.00145608. View

Austin E, Ma L, Leduc C, Rosenzweig E, Borczuk A, Phillips 3rd J . Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012; 5(3):336-43. PMC: 3380156. DOI: 10.1161/CIRCGENETICS.111.961888. View

Valerio C, Schreiber B, E Handler C, Denton C, Coghlan J . Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum. 2013; 65(4):1074-84. DOI: 10.1002/art.37838. View

Ma L, Roman-Campos D, Austin E, Eyries M, Sampson K, Soubrier F . A novel channelopathy in pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):351-361. PMC: 3792227. DOI: 10.1056/NEJMoa1211097. View

Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C . EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2013; 46(1):65-9. DOI: 10.1038/ng.2844. View

Austin E, Loyd J . The genetics of pulmonary arterial hypertension. Circ Res. 2014; 115(1):189-202. PMC: 4137413. DOI: 10.1161/CIRCRESAHA.115.303404. View

Taboada D, Pepke-Zaba J, Jenkins D, Berman M, Treacy C, Cannon J . Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014; 44(6):1635-45. DOI: 10.1183/09031936.00050114. View

Sitbon O, Benza R, Badesch D, Barst R, Elliott C, Gressin V . Validation of two predictive models for survival in pulmonary arterial hypertension. Eur Respir J. 2015; 46(1):152-64. DOI: 10.1183/09031936.00004414. View

10.

Farber H, Miller D, Poms A, Badesch D, Frost A, Muros-Le Rouzic E . Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015; 148(4):1043-54. DOI: 10.1378/chest.15-0300. View

11.

Galie N, Barbera J, Frost A, Ghofrani H, Hoeper M, McLaughlin V . Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med. 2015; 373(9):834-44. DOI: 10.1056/NEJMoa1413687. View

12.

Hassoun P, Zamanian R, Damico R, Lechtzin N, Khair R, Kolb T . Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015; 192(9):1102-10. PMC: 4642204. DOI: 10.1164/rccm.201507-1398OC. View

13.

Maron B, Hess E, Maddox T, Opotowsky A, Tedford R, Lahm T . Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016; 133(13):1240-8. PMC: 4811678. DOI: 10.1161/CIRCULATIONAHA.115.020207. View

14.

Best D, Sumner K, Smith B, Damjanovich-Colmenares K, Nakayama I, Brown L . EIF2AK4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension. Chest. 2016; 151(4):821-828. DOI: 10.1016/j.chest.2016.11.014. View

15.

Dawes T, de Marvao A, Shi W, Fletcher T, Watson G, Wharton J . Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study. Radiology. 2017; 283(2):381-390. PMC: 5398374. DOI: 10.1148/radiol.2016161315. View

16.

Assad T, Maron B, Robbins I, Xu M, Huang S, Harrell F . Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiol. 2017; 2(12):1361-1368. PMC: 5814998. DOI: 10.1001/jamacardio.2017.3882. View

17.

Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A . Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality. Am J Respir Crit Care Med. 2017; 197(4):509-516. DOI: 10.1164/rccm.201706-1215OC. View

18.

Caravita S, Dewachter C, Soranna D, Carolino DAraujo S, Khaldi A, Zambon A . Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a meta-analysis. Eur Respir J. 2018; 51(4). DOI: 10.1183/13993003.02427-2017. View

19.

Vanderpool R, Saul M, Nouraie M, Gladwin M, Simon M . Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2018; 3(4):298-306. PMC: 5875307. DOI: 10.1001/jamacardio.2018.0128. View

20.

Coghlan J, Wolf M, Distler O, Denton C, Doelberg M, Harutyunova S . Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J. 2018; 51(4). DOI: 10.1183/13993003.01197-2017. View